Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Applications of microwave-assisted organic synthesis on the multigram scale.

Wolkenberg SE, Shipe WD, Lindsley CW, Guare JP, Pawluczyk JM.

Curr Opin Drug Discov Devel. 2005 Nov;8(6):701-8. Review.

PMID:
16312146
2.

A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.

DeFeo-Jones D, Brady SF, Feng DM, Wong BK, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Pawluczyk JM, Wai J, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Garsky VM, Freidinger R, Oliff A, Jones RE.

Mol Cancer Ther. 2002 May;1(7):451-9.

3.

Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.

Brady SF, Pawluczyk JM, Lumma PK, Feng DM, Wai JM, Jones R, DeFeo-Jones D, Wong BK, Miller-Stein C, Lin JH, Oliff A, Freidinger RM, Garsky VM.

J Med Chem. 2002 Oct 10;45(21):4706-15.

PMID:
12361397
4.

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.

Williams PD, Bock MG, Evans BE, Freidinger RM, Gallicchio SN, Guidotti MT, Jacobson MA, Kuo MS, Levy MR, Lis EV, Michelson SR, Pawluczyk JM, Perlow DS, Pettibone DJ, Quigley AG, Reiss DR, Salvatore C, Stauffer KJ, Woyden CJ.

Bioorg Med Chem Lett. 1999 May 3;9(9):1311-6.

PMID:
10340620
5.

Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.

Kuo MS, Bock MG, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, Perlow DS, Pettibone DJ, Quigley AG, Reiss DR, Williams PD, Woyden CJ.

Bioorg Med Chem Lett. 1998 Nov 3;8(21):3081-6.

PMID:
9873680
6.

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.

Bell IM, Erb JM, Freidinger RM, Gallicchio SN, Guare JP, Guidotti MT, Halpin RA, Hobbs DW, Homnick CF, Kuo MS, Lis EV, Mathre DJ, Michelson SR, Pawluczyk JM, Pettibone DJ, Reiss DR, Vickers S, Williams PD, Woyden CJ.

J Med Chem. 1998 Jun 4;41(12):2146-63.

PMID:
9622556
7.

1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.

Williams PD, Clineschmidt BV, Erb JM, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, Pettibone DJ, Reiss DR, Veber DF, et al.

J Med Chem. 1995 Nov 10;38(23):4634-6. No abstract available.

PMID:
7473590
8.

Conformationally constrained o-tolylpiperazine camphorsulfonamide oxytocin antagonists. Structural modifications that provide high receptor affinity and suggest a bioactive conformation.

Williams PD, Ball RG, Clineschmidt BV, Culberson JC, Erb JM, Freidinger RM, Pawluczyk JM, Perlow DS, Pettibone DJ, Veber DF.

Bioorg Med Chem. 1994 Sep;2(9):971-85.

PMID:
7712132
9.

Nanomolar-affinity, non-peptide oxytocin receptor antagonists.

Evans BE, Lundell GF, Gilbert KF, Bock MG, Rittle KE, Carroll LA, Williams PD, Pawluczyk JM, Leighton JL, Young MB, et al.

J Med Chem. 1993 Dec 10;36(25):3993-4005.

PMID:
8258821

Supplemental Content

Loading ...
Support Center